Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$97,465 Mln
P/E Ratio
17.87
P/B Ratio
5.7
Industry P/E
28.06
Debt to Equity
2.65
ROE
-0.39 %
ROCE
-12.93 %
Div. Yield
5.09 %
Book Value
8.05
EPS
3.26
CFO
$84,297.00 Mln
EBITDA
$102,671.00 Mln
Net Profit
$29,834.00 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bristol-Myers Squibb (BMY)
| -15.31 | -21.54 | -19.73 | -1.96 | -14.17 | -5.11 | -3.13 |
|
BSE Sensex
| 1.23 | 1.57 | 3.97 | 7.26 | 11.47 | 20.39 | 11.18 |
|
S&P 100
| -7.84 | -4.23 | -10.10 | 11.63 | 11.27 | 15.45 | 11.18 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Bristol-Myers Squibb (BMY)
| 10.14 | -28.69 | 15.40 | 2.88 | 0.41 | 27.74 | -12.83 |
|
S&P 100
| 29.04 | 30.83 | -22.12 | 27.55 | 19.30 | 29.47 | -5.82 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 0.42 | 11.49 | -- | -80.19 | |
| 9.98 | 138.58 | -- | -568.22 | |
| 154.58 | 371,930.30 | 17.19 | 29.42 | |
| 1.06 | 15.68 | -- | -277.53 |
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas.... The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey. Read more
CEO & Chairman
Dr. Christopher S. Boerner Ph.D.
CEO & Chairman
Dr. Christopher S. Boerner Ph.D.
Headquarters
Princeton, NJ
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bristol-Myers Squibb Company (BMY) stood at $ 116,497 Mln as on 31-Mar-25
The share price of Bristol-Myers Squibb Company (BMY) is $47.90 (NYSE) as of 25-Apr-2025 16:22 EDT. Bristol-Myers Squibb Company (BMY) has given a return of -14.17% in the last 3 years.
Bristol-Myers Squibb Company (BMY) has a market capitalisation of $ 97,465 Mln as on 25-Apr-2025. As per Value Research classification, it is a Large Cap company.
The P/B ratio of Bristol-Myers Squibb Company (BMY) is 5.70 times as on 25-Apr-2025, a 13% premium to its peers’ median range of 5.04 times.
The P/E ratio of Bristol-Myers Squibb Company (BMY) is 17.87 times as on 25-Apr-2025, a 36% discount to its peers’ median range of 28.06 times.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bristol-Myers Squibb Company (BMY) and enter the required number of quantities and click on buy to purchase the shares of Bristol-Myers Squibb Company (BMY).
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of relapsed/refractory multiple myeloma; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Reblozyl to treat anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Cobenfy to treat schizophrenia in adults; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; and Abraxane for the treatment of breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.
The CEO & director of Dr. Christopher S. Boerner Ph.D.. is Bristol-Myers Squibb Company (BMY), and CFO & Sr. VP is Dr. Christopher S. Boerner Ph.D..
There is no promoter pledging in Bristol-Myers Squibb Company (BMY).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
38,015
|
|
|
13
|
|
|
1
|
|
|
1
|
| Bristol-Myers Squibb Company (BMY) | Ratios |
|---|---|
|
Return on equity(%)
|
31.28
|
|
Operating margin(%)
|
9.78
|
|
Net Margin(%)
|
11.38
|
|
Dividend yield(%)
|
5.09
|
No, TTM profit after tax of Bristol-Myers Squibb Company (BMY) was $0 Mln.
$-0.79
(
